DMX200 competition including SGLT2 Inhibitors, page-14

Gee, it would be nice to know how many of the available patients have gained access to the SAS. Even just a raw number of applications. If there’s 50 applications with the SAS, then we know something is afoot. Because every patient in both the FSGS and DM studies was exposed to DXB-200. It’s not like half of them received sugar tabs, and half received the active drug. Their physicians would have a very good idea of when they were taking the active drug (if it works, of course) The mere fact that there’s been applications to the SAS suggests that it works. If there was no improvement whilst on the active drug, then there’d be no reason to apply. Leave it with me: I’ll make some enquiries later today.